These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28783977)

  • 21. Recent advances and developments in treatment strategies against pancreatic cancer.
    Fryer RA; Galustian C; Dalgleish AG
    Curr Clin Pharmacol; 2009 May; 4(2):102-12. PubMed ID: 19442075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer.
    Fendrich V; Lauth M
    Expert Opin Ther Targets; 2014 Nov; 18(11):1277-83. PubMed ID: 25078025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials.
    Kaur J; Singh P; Enzler T; Sahai V
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):103-129. PubMed ID: 33734833
    [No Abstract]   [Full Text] [Related]  

  • 24. Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.
    Arlt A; Schäfer H
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1251-1254. PubMed ID: 27666721
    [No Abstract]   [Full Text] [Related]  

  • 25. Emerging protein kinase inhibitors for treating pancreatic cancer.
    Furuse J; Nagashima F
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of pancreatic cancer. Actuality and perspective].
    Bittoni A; Andrikou K; Lanese A; Santoni M; Pellei C; Faloppi L; Del Prete M; Giampieri R; Cascinu S
    Recenti Prog Med; 2015 May; 106(5):208-16. PubMed ID: 25994537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
    Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Xu J; Jones L; Chang K; Johnston F; Trinkaus K; Hotchkiss RS; Mach RH; Hawkins WG
    Mol Cancer; 2007 Jul; 6():48. PubMed ID: 17631687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer.
    Kelsen D
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):58-66. PubMed ID: 8091242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug development and clinical trial design in pancreatico-biliary malignancies.
    Harrington J; Carter L; Basu B; Cook N
    Curr Probl Cancer; 2018; 42(1):73-94. PubMed ID: 29402439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies for pancreatic adenocarcinoma.
    Lowery M; O'Reilly EM
    Minerva Chir; 2009 Oct; 64(5):501-19. PubMed ID: 19859040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced pancreatic carcinoma: current treatment and future challenges.
    Stathis A; Moore MJ
    Nat Rev Clin Oncol; 2010 Mar; 7(3):163-72. PubMed ID: 20101258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
    Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
    Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of chemotherapy in the treatment of adenocarcinoma of the pancreas.
    Fennelly D; Kelsen DP
    Hepatogastroenterology; 1996; 43(8):356-62. PubMed ID: 8714228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
    Gromisch C; Qadan M; Machado MA; Liu K; Colson Y; Grinstaff MW
    Cancer Res; 2020 Aug; 80(16):3179-3192. PubMed ID: 32220831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging antibodies for the treatment of pancreatic cancer.
    Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biotherapeutic approaches to pancreatic cancer.
    Rosenberg L; Lipsett M
    Expert Opin Biol Ther; 2003 Apr; 3(2):319-37. PubMed ID: 12662145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer.
    Liu H; Ma Q; Xu Q; Lei J; Li X; Wang Z; Wu E
    Curr Pharm Des; 2012; 18(17):2395-403. PubMed ID: 22372500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Masitinib in treatment of pancreatic cancer.
    Waheed A; Purvey S; Saif MW
    Expert Opin Pharmacother; 2018 May; 19(7):759-764. PubMed ID: 29638149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.